Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders

被引：237

作者：

Conn, P. Jeffrey ^{[1
]}

Jones, Carrie K. ^{[1
]}

Lindsley, Craig W. ^{[1
,2
]}

机构：

[1] Vanderbilt Univ Sch Med, Dept Pharmacol, Vanderbilt Program Drug Discovery, Nashville, TN 37232 USA

[2] Vanderbilt Univ, Dept Chem, Nashville, TN 37232 USA

来源：

TRENDS IN PHARMACOLOGICAL SCIENCES | 2009年 / 30卷 / 03期

基金：

美国国家卫生研究院;

关键词：

BEHAVIORAL SYMPTOMS; ALZHEIMERS-DISEASE; CHOLINESTERASE-INHIBITORS; NEUROPSYCHIATRIC SYMPTOMS; ACETYLCHOLINE-RECEPTORS; AGONIST XANOMELINE; ACTIVATION; COOPERATIVITY; HYPERACTIVITY; AMPHETAMINE;

D O I：

10.1016/j.tips.2008.12.002

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Muscarinic acetylcholine receptors (mAChRs) have long been viewed as viable targets for novel therapeutic agents for the treatment of Alzheimer's disease (AD) and other disorders involving impaired cognitive function. More recent evidence indicates that mAChR activators might also have utility in treating psychosis and other symptoms associated with schizophrenia and other central nervous system (CNS) disorders. Efforts to develop mAChR subtype-selective agonists have been hampered by difficulty in achieving high selectivity for individual mAChR subtypes important for CNS function (M-1 and M-4) and adverse effects due to activation of peripheral mAChRs (especially M-2 and M-3). Major advances have now been achieved in the discovery of allosteric agonists and positive allosteric modulators of M-1 and M-4 that show greater selectivity for individual mAChR subtypes than do previous mAChR agonists. Early studies indicate that these allosteric mAChR activators have properties needed for optimization as potential clinical candidates and have robust effects in animal models that predict efficacy in the treatment of AD, schizophrenia and related disorders.

引用

页码：148 / 155

页数：8

共 54 条

[1] Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice [J].